These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 36351931)

  • 41. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Zhu FC; Guan XH; Li YH; Huang JY; Jiang T; Hou LH; Li JX; Yang BF; Wang L; Wang WJ; Wu SP; Wang Z; Wu XH; Xu JJ; Zhang Z; Jia SY; Wang BS; Hu Y; Liu JJ; Zhang J; Qian XA; Li Q; Pan HX; Jiang HD; Deng P; Gou JB; Wang XW; Wang XH; Chen W
    Lancet; 2020 Aug; 396(10249):479-488. PubMed ID: 32702299
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial.
    Hui AM; Li J; Zhu L; Tang R; Ye H; Lin M; Ge L; Wang X; Peng F; Wu Z; Guo X; Shi Y; Pan H; Zhu J; Song Z; Qiu J; Wang W; Zheng J; Ozhelvaci O; Shpyro S; Bushway M; Derhovanessian E; Kühnle MC; Luxemburger U; Muik A; Shishkova Y; Khondker Z; Hu S; Lagkadinou E; Şahin U; Türeci Ö; Zhu F
    Lancet Reg Health West Pac; 2022 Dec; 29():100586. PubMed ID: 36120090
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial.
    Schuind A; Segall N; Drame M; Innis BL
    J Infect Dis; 2015 Aug; 212(4):531-41. PubMed ID: 25722291
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Booster Dose of CoronaVac Increases Neutralizing Antibodies and T Cells that Recognize Delta and Omicron Variants of Concern.
    Schultz BM; Melo-González F; Duarte LF; Gálvez NMS; Pacheco GA; Soto JA; Berríos-Rojas RV; González LA; Moreno-Tapia D; Rivera-Pérez D; Ríos M; Vázquez Y; Hoppe-Elsholz G; Andrade-Parra CA; Vallejos OP; Piña-Iturbe A; Iturriaga C; Urzua M; Navarrete MS; Rojas Á; Fasce R; Fernández J; Mora J; Ramírez E; Gaete-Argel A; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Weiskopf D; Grifoni A; Sette A; Zeng G; Meng W; ; González-Aramundiz JV; González PA; Abarca K; Kalergis AM; Bueno SM
    mBio; 2022 Aug; 13(4):e0142322. PubMed ID: 35946814
    [TBL] [Abstract][Full Text] [Related]  

  • 45. AS03 adjuvant enhances the magnitude, persistence, and clonal breadth of memory B cell responses to a plant-based COVID-19 vaccine in humans.
    Grigoryan L; Feng Y; Bellusci L; Lai L; Wali B; Ellis M; Yuan M; Arunachalam PS; Hu M; Kowli S; Gupta S; Maysel-Auslender S; Maecker HT; Samaha H; Rouphael N; Wilson IA; Moreno AC; Suthar MS; Khurana S; Pillet S; Charland N; Ward BJ; Pulendran B
    Sci Immunol; 2024 Apr; 9(94):eadi8039. PubMed ID: 38579013
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine.
    Leroux-Roels I; Maes C; Joye J; Jacobs B; Jarczowski F; Diessner A; Janssens Y; Waerlop G; Tamminen K; Heinimäki S; Blazevic V; Leroux-Roels G; Klimyuk V; Adachi H; Hiruta K; Thieme F
    Front Immunol; 2022; 13():1021500. PubMed ID: 36275772
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunity duration of a recombinant adenovirus type-5 vector-based Ebola vaccine and a homologous prime-boost immunisation in healthy adults in China: final report of a randomised, double-blind, placebo-controlled, phase 1 trial.
    Li JX; Hou LH; Meng FY; Wu SP; Hu YM; Liang Q; Chu K; Zhang Z; Xu JJ; Tang R; Wang WJ; Liu P; Hu JL; Luo L; Jiang R; Zhu FC; Chen W
    Lancet Glob Health; 2017 Mar; 5(3):e324-e334. PubMed ID: 28017642
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
    Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity and safety of an AS03(A)-adjuvanted H5N1 influenza vaccine in a Taiwanese population.
    Hwang SJ; Chang SC; Yu CJ; Chan YJ; Chen TJ; Hsieh SL; Lai HY; Lin MH; Liu JY; Ong G; Roman F; Dramé M; Bock HL; Yang PC
    J Formos Med Assoc; 2011 Dec; 110(12):780-6. PubMed ID: 22248833
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunogenicity and protective efficacy of GBP510/AS03 vaccine against SARS-CoV-2 delta challenge in rhesus macaques.
    Jacob-Dolan C; Yu J; McMahan K; Giffin V; Chandrashekar A; Martinot AJ; Anioke T; Powers OC; Hall K; Hope D; Miller J; Hachmann NP; Chung B; Gardner S; Sellers D; Barrett J; Lewis MG; Andersen H; Kleanthous H; Seo KW; Lee SJ; Park YW; Kim H; Barouch DH
    NPJ Vaccines; 2023 Feb; 8(1):23. PubMed ID: 36823160
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2.
    Leal L; Pich J; Ferrer L; Nava J; Martí-Lluch R; Esteban I; Pradenas E; Raïch-Regué D; Prenafeta A; Escobar K; Pastor C; Ribas-Aulinas M; Trinitè B; Muñoz-Basagoiti J; Domenech G; Clotet B; Corominas J; Corpes-Comes A; Garriga C; Barreiro A; Izquierdo-Useros N; Arnaiz JA; Soriano A; Ríos J; Nadal M; Plana M; Blanco J; Prat T; Torroella E; Ramos R;
    NPJ Vaccines; 2023 Sep; 8(1):147. PubMed ID: 37775521
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Whole-blood cytokine secretion assay as a high-throughput alternative for assessing the cell-mediated immunity profile after two doses of an adjuvanted SARS-CoV-2 recombinant protein vaccine candidate.
    De Rosa SC; Cohen KW; Bonaparte M; Fu B; Garg S; Gerard C; Goepfert PA; Huang Y; Larocque D; McElrath MJ; Morris D; Van der Most R; de Bruyn G; Pagnon A
    Clin Transl Immunology; 2022; 11(1):e1360. PubMed ID: 35035955
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein Vaccine.
    Dayan GH; Rouphael N; Walsh SR; Chen A; Grunenberg N; Allen M; Antony J; Asante KP; Bhate AS; Beresnev T; Bonaparte MI; Ceregido MA; Dobrianskyi D; Fu B; Grillet MH; Keshtkar-Jahromi M; Juraska M; Kee JJ; Kibuuka H; Koutsoukos M; Masotti R; Michael NL; Reynales H; Robb ML; Villagómez Martínez SM; Sawe F; Schuerman L; Tong T; Treanor J; Wartel TA; Diazgranados CA; Chicz RM; Gurunathan S; Savarino S; Sridhar S;
    medRxiv; 2023 Jan; ():. PubMed ID: 36523415
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plant-Based COVID-19 Vaccines: Current Status, Design, and Development Strategies of Candidate Vaccines.
    Maharjan PM; Choe S
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579229
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19.
    Gobeil P; Pillet S; Boulay I; Charland N; Lorin A; Cheng MP; Vinh DC; Boutet P; Van Der Most R; Roman F; Ceregido MA; Landry N; D'Aoust MA; Ward BJ
    Nat Commun; 2022 Nov; 13(1):6905. PubMed ID: 36371408
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exploring recent progress of molecular farming for therapeutic and recombinant molecules in plant systems.
    Bharathi JK; Suresh P; Prakash MAS; Muneer S
    Heliyon; 2024 Sep; 10(18):e37634. PubMed ID: 39309966
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An overview of descriptors to capture protein properties - Tools and perspectives in the context of QSAR modeling.
    Emonts J; Buyel JF
    Comput Struct Biotechnol J; 2023; 21():3234-3247. PubMed ID: 38213891
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunogenicity and safety of adjuvant-associated COVID-19 vaccines: A systematic review and meta-analysis of randomized controlled trials.
    Cheng MQ; Li R; Luo X; Chen JY; Bai ZP; Zhao P; Weng ZY; Song G
    Heliyon; 2023 Dec; 9(12):e22858. PubMed ID: 38125524
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies.
    Wynne C; Balgos A; Li J; Hamilton P; Tirador L; Jaen AM; Mo C; Yue Z; Ma Y; Wang Q; Wen R; Yao Z; Yu J; Yao W; Zhang J; Zheng H; Hong K; Zhu F; Liu Y
    Infect Dis Ther; 2024 Jan; 13(1):57-78. PubMed ID: 38103161
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Developing an efficient MGCR microneedle nanovaccine patch for eliciting Th 1 cellular response against the SARS-CoV-2 infection.
    Gao A; Chen Y; Liang H; Cui X; Zhang A; Cui D
    Theranostics; 2023; 13(14):4821-4835. PubMed ID: 37771766
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.